FDA: Access to Mifepristone Back at the Supreme Court In response to emergency appeals filed by Danco and GenBioPro, on May 4, 2026, Justice Alito issued a one-week administrative stay of the 5th Circuit’s decision in the Louisiana v. The FDA 2023 dispensing policy allowing mifepristone to be mailed remains in place pending a decision from the Supreme Court. The Supreme Court is reviewing the 5th Circuit Court of Appeals order on May 1, 2026, which temporarily reinstated an in-person dispensing requirement for mifepristone nationwide. Medication abortion—most commonly a two-drug regimen of mifepristone and misoprostol—has become a central legal battleground in the years since Dobbs v.
Latest development
Media Coverage · May 6, 2026
The court issued an order.
newspaper Read articleCourt
Court not identified
Awaiting court metadata
Docket
Not captured
Appellate
Stage
Active litigation
Active
Filed
Date unavailable
Not in the available feed
Latest Filing
Louisiana v . FDA : Access to Mifepristone Back at the Supreme Court
Media Coverage · May 06, 2026
Coverage
1 article
1 source tracked
Participants
1 Defendant
2 linked entities
Judge
Not assigned in feed
The court metadata has not been resolved yet, so Juryvine is keeping the page conservative until a reliable court match lands.
The newest docket activity we have is a media coverage dated May 06, 2026.
The visible party/entity graph currently includes FDA : Access to Mifepristone Back at the Supreme Court and others.
Press monitoring has found 1 related article from 1 distinct source.
Louisiana v. FDA: Access to Mifepristone Back at the Supreme Court is an active appellate matter.
The main identified defendant or respondent is FDA: Access to Mifepristone Back at the Supreme Court. The case is currently organized around Current docket activity and next procedural step, Agency action and administrative review, Issues preserved for appellate review, Appellate posture and standard of review.
The available docket gives enough signal to track the case, but not enough to overstate the merits. This page will become more useful as filings, orders, hearings, and party appearances add detail.
On May 6, 2026, the docket recorded a media coverage: The court issued an order.
The next thing to watch is whether the latest media coverage produces a substantive order, a scheduling change, a settlement signal, or a filing that clarifies the parties' positions.
FDA: Access to Mifepristone Back at the Supreme Court In response to emergency appeals filed by Danco and GenBioPro, on May 4, 2026, Justice Alito issued a one-week administrative stay of the 5th Circuit’s decision in the Louisiana v. The FDA 2023 dispensing policy allowing mifepristone to be mailed remains in place pending a decision from the Supreme Court. The Supreme Court is reviewing the 5th Circuit Court of Appeals order on May 1, 2026, which temporarily reinstated an in-person dispensing
Open original open_in_newJuryvine summaries are generated from court records. Expand "Source" on any row to see the underlying filing.
The court issued an order.
FDA: Access to Mifepristone Back at the Supreme Court In response to emergency appeals filed by Danco and GenBioPro, on May 4, 2026, Justice Alito issued a one-week administrative stay …
Sources tracked
1 outlet · 1 article
Timeline events
1 record on file
Last updated
10 hours, 22 minutes ago
Juryvine aggregates docket entries from PACER/CourtListener, press coverage, and GDELT signals. Ingestion timestamps do not appear in the What Changed feed — that reflects real court activity only.